Viatris (VTRS) Other Non-Current Assets (2019 - 2026)
Viatris' (VTRS) quarterly Other Non-Current Assets came in at $1.1 billion in Q1 2026, down 51.38% year-on-year from $2.3 billion in Q1 2025, and down 40.92% quarter-over-quarter from $1.9 billion in Q4 2025.
Viatris (VTRS) Other Non-Current Assets (2019 - 2026) Analysis & Trends
Viatris' Other Non-Current Assets history runs 8 years deep, the most recent figure standing at $1.1 billion for Q1 2026.
- On a quarterly basis, Other Non-Current Assets fell 51.38% year-over-year to $1.1 billion in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 51.38% decrease from a year earlier, with the FY2025 full-year figure at $1.9 billion, down 20.58% from the prior year.
- Other Non-Current Assets retreated to $1.1 billion in Q1 2026 per VTRS's latest filing, from $1.9 billion in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $2.8 billion in Q4 2023 and bottomed at $230.3 million in Q4 2022.
- The 5-year median for Other Non-Current Assets is $1.9 billion (2025), against an average of $1.8 billion.
- Across the five-year window, Other Non-Current Assets slumped 80.33% in 2022 and jumped 1109.73% in 2023, its largest moves.
- Year by year, Other Non-Current Assets stood at $230.3 million in 2022, then soared by 1109.73% to $2.8 billion in 2023, then retreated by 15.4% to $2.4 billion in 2024, then declined by 20.58% to $1.9 billion in 2025, then slumped by 40.92% to $1.1 billion in 2026.
- Per Business Quant, the three latest VTRS Other Non-Current Assets figures stand at $1.1 billion (Q1 2026), $1.9 billion (Q4 2025), and $1.9 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | 49.22 Mn |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 377.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 351.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 491.06 Mn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 233.20 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | 169,000.00 |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 1.11 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 73.60 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 295.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 4.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.11 Bn |
| Dec 31, 2025 | 1.87 Bn |
| Sep 30, 2025 | 1.89 Bn |
| Jun 30, 2025 | 2.00 Bn |
| Mar 31, 2025 | 2.27 Bn |
| Dec 31, 2024 | 2.36 Bn |
| Jun 30, 2024 | 2.45 Bn |
| Mar 31, 2024 | 2.52 Bn |
| Dec 31, 2023 | 2.79 Bn |
| Sep 30, 2023 | 427.30 Mn |
| Jun 30, 2023 | 2.35 Bn |
| Mar 31, 2023 | 2.42 Bn |
| Dec 31, 2022 | 230.30 Mn |
| Sep 30, 2022 | 1.43 Bn |
| Jun 30, 2022 | 1.47 Bn |
| Mar 31, 2022 | 1.34 Bn |
| Dec 31, 2021 | 1.17 Bn |
| Sep 30, 2021 | 1.04 Bn |
| Jun 30, 2021 | 1.03 Bn |
| Mar 31, 2021 | 1.02 Bn |